Moderna and BioNTech: The mRNA Platform Is a Faster Way to Fail

Update August 9, 2026: On the day this article was published, mFLUSIVA (mRNA-1010) was approved — the first mRNA-based seasonal influenza vaccine in the US. MRNA closed at $56.26 on August 5, at $59.17 on August 7 (Polygon). The approval gives Moderna a second commercial product but does not change the core economics thesis: $2.4B annual cash burn against $6.9B cash position requires multiple successful launches. See our mFLUSIVA approval coverage.

Update August 21, 2026: The thesis just got its most important data point. On August 19, Moderna/Merck’s intismeran (mRNA-4157) cancer vaccine cleared Phase 3 INTerpath-001 in melanoma, and MRNA surged 177% to $174.38 before pulling back to $133.32 on August 20 (Polygon). This converts the cancer vaccine from “Phase 2 in 157 patients” to a Phase 3-validated asset — directly addressing the “zero non-COVID approvals” critique at the core of this article. See our breaking coverage: Moderna Surges 177% as Intismeran Clears Phase 3 Melanoma Trial.

The market values Moderna and BioNTech as a bet on mRNA.

The platform thesis

The pitch is simple: design an mRNA sequence, encapsulate it in a lipid nanoparticle (LNP), inject it. The same delivery system works for flu, RSV, cancer vaccines, and rare disease protein replacement. This should reduce R&D cost per drug, shorten development timelines, and increase the probability of success across indications.

Moderna’s COVID vaccine proved the technology works. Spikevax generated $19.2 billion in 2022 revenue. The platform delivered a vaccine in 11 months. That is real.

The problem is everything that happened after.

The cost reality

Moderna has spent over $6 billion on R&D since 2020. The result: zero non-COVID approved products. Revenue collapsed from $19.2 billion in 2022 to an estimated $2-3 billion in 2026. The pipeline has produced notable failures: mRNA-1010 flu vaccine showed mixed efficacy, mRNA-1403 norovirus missed its Phase 3 interim endpoint (the stock dropped 17%), and mRNA-4157 cancer vaccine showed positive Phase 2 data in a tiny trial of 157 patients.

BioNTech has spent roughly $6 billion over the same period. Its strategy has shifted under CEO Sean Oelkers, who is refocusing the pipeline toward oncology. BioNTech’s BNT122 personalized cancer vaccine showed promising Phase 2 data in melanoma, but the Phase 3 readout is years away. For a deeper look at BioNTech’s strategic pivot, see our BioNTech pipeline analysis.

The R&D cost per approved non-COVID product, as of today, is infinite. Zero approvals divided by $12 billion equals infinity.

Manufacturing economics

mRNA manufacturing uses in vitro transcription rather than cell culture. This is supposed to be cheaper and faster to scale. In practice, the cost advantages are real for vaccines but less clear for therapeutics. mRNA is inherently unstable. Every dose requires cold chain logistics. The LNPs that protect mRNA from degradation are themselves expensive and supply-constrained.

For prophylactic vaccines, where you need millions of doses at low cost, mRNA’s speed advantage matters. For rare disease protein replacement, where you need sustained expression at therapeutic levels, mRNA’s instability is a fundamental limitation. The body degrades mRNA in hours. Protein replacement therapy requires expression for weeks. This is not a manufacturing problem. It is a biology problem.

The probability of success problem

Moderna’s pipeline success rate outside COVID is instructive. The company has advanced roughly 15 candidates into clinical trials since 2020. The results:

• mRNA-1010 flu: mixed efficacy, PDUFA August 5, 2026 — approved August 5 as mFLUSIVA, the first mRNA seasonal flu vaccine in the US. For our analysis, see the flu vaccine PDUFA thesis and the mFLUSIVA approval coverage.
• mRNA-1403 norovirus: Phase 3 interim miss.
• mRNA-4157 cancer vaccine: Phase 2 positive, Phase 3 ongoing.
• mRNA-1345 RSV: approved.
• mRNA-1287 Zika: Phase 2 ongoing.
• mRNA-1015 next-gen flu: Phase 1.

One approval (RSV) out of 15 candidates is a 6.7% approval rate. That is below the industry average for all therapeutic modalities. The platform is not beating the odds. It is matching them, at best.

BioNTech vs Moderna: two strategies

BioNTech is pivoting to oncology. CEO Sean Oelkers has narrowed the pipeline to cancer vaccines and immunotherapies. The rationale: oncology commands higher prices and the personalized cancer vaccine approach (BNT122) has genuine Phase 2 data. The risk: oncology trials are long and expensive, and BioNTech is competing with Merck’s Keytruda-based combinations.

Moderna is betting on latent virus vaccines, rare disease, and the remaining COVID franchise. The risk: vaccines are low-margin, and the rare disease approach requires solving the protein expression durability problem that mRNA has not solved yet.

For a primer on how the underlying technology works, see our mRNA platform explainer.

The cash burn question

Moderna had approximately $10 billion in cash at its peak. The company is burning roughly $3-4 billion per year on R&D and operating expenses. At that rate, the runway is roughly 2-3 years before the company needs to raise capital or cut spending. If the flu vaccine PDUFA on August 5 results in approval, it adds revenue. If not, the burn accelerates.

BioNTech had roughly $18 billion in cash at its peak and is burning roughly $2-3 billion per year. Its runway is longer, but the pivot to oncology means longer trial timelines and more expensive late-stage development.

The verdict

The mRNA platform is a genuine technological advance for vaccines. It is not a general-purpose drug discovery engine. The platform economics look worse than traditional biologics for therapeutics, not better. A monoclonal antibody costs $1-2 billion to develop and has a 10-15% probability of success. An mRNA therapeutic costs the same and has the same probability of success, but with an added instability problem.

At $22.8 billion, Moderna is pricing in roughly $8 billion in COVID franchise value plus $15 billion in pipeline optionality. The pipeline has produced one approval in five years. The math does not support the valuation. At $22.9 billion, BioNTech is pricing in a similar optionality premium, but the oncology pivot at least has a clearer path to high-value products.

The pattern here is clear: platform companies trade on narrative until the data arrives. Moderna’s data has been mixed. BioNTech’s data is years away. For investors who want exposure to the mRNA space, see our mRNA sector roundup.

I would not bet against the technology. I would not pay $22 billion for it either.

Source: Moderna Q2 2026 financial results